Glioblastoma Treatment Response Accurately Modeled Using Patient-Derived Organoids

Researchers demonstrate that lab-grown tumor organoids can predict glioblastoma patients' responses to CAR-T cell therapy in real time, paving the way for personalized treatments.

• Scientists at the University of Pennsylvania used glioblastoma organoids to mirror patient responses to CAR-T cell therapy in a Phase I clinical trial.
• The organoids, derived from patients' tumors, accurately predicted tumor shrinkage and neurotoxicity risks, enabling dose optimization.
• Organoids can be generated in just 2–3 weeks, providing actionable insights during the recovery period after surgery and before therapy begins.
• The study highlights the potential of organoids to model the complex tumor microenvironment and stratify patients for personalized treatments and clinical trials.
• This research marks a significant step toward improving outcomes for glioblastoma, an aggressive brain cancer with limited treatment options and poor survival rates.

3 Articles

GEN Neuroscience News Technology Networks